- Home
- IAF vs SPRO Comparison
IAF vs SPRO Comparison
Compare IAF & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAF
- SPRO
- Stock Information
- Founded
- IAF 1985
- SPRO 2013
- Country
- IAF United States
- SPRO United States
- Employees
- IAF N/A
- SPRO N/A
- Industry
- IAF Finance/Investors Services
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- IAF Finance
- SPRO Health Care
- Exchange
- IAF Nasdaq
- SPRO Nasdaq
- Market Cap
- IAF 124.2M
- SPRO 128.9M
- IPO Year
- IAF N/A
- SPRO 2017
- Fundamental
- Price
- IAF $13.67
- SPRO $2.43
- Analyst Decision
- IAF
- SPRO Buy
- Analyst Count
- IAF 0
- SPRO 4
- Target Price
- IAF N/A
- SPRO $5.00
- AVG Volume (30 Days)
- IAF 90.4K
- SPRO 1.2M
- Earning Date
- IAF 01-01-0001
- SPRO 11-13-2025
- Dividend Yield
- IAF 11.44%
- SPRO N/A
- EPS Growth
- IAF N/A
- SPRO N/A
- EPS
- IAF N/A
- SPRO N/A
- Revenue
- IAF N/A
- SPRO $48,576,000.00
- Revenue This Year
- IAF N/A
- SPRO N/A
- Revenue Next Year
- IAF N/A
- SPRO N/A
- P/E Ratio
- IAF N/A
- SPRO N/A
- Revenue Growth
- IAF N/A
- SPRO N/A
- 52 Week Low
- IAF $3.60
- SPRO $0.51
- 52 Week High
- IAF $4.59
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- IAF 95.38
- SPRO 57.02
- Support Level
- IAF $4.54
- SPRO $2.16
- Resistance Level
- IAF $14.15
- SPRO $2.42
- Average True Range (ATR)
- IAF 0.79
- SPRO 0.12
- MACD
- IAF 1.07
- SPRO -0.00
- Stochastic Oscillator
- IAF 95.10
- SPRO 52.45
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.